Drug intelligence / Profile preview

AT313

Development stage: Unknown
Lead developer: Autonomous Therapeutics
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

AT313 is a preclinical candidate developed by Autonomous Therapeutics, utilizing their precision encrypted RNA (encRNA) technology. It is being developed in collaboration with MiNK Therapeutics to create therapies for metastatic solid tumors, including microsatellite stable (MSS) colorectal cancer. The drug is designed to precisely target and eliminate cancer cells while sparing healthy tissue, and is intended to be evaluated in combination with MiNK's allogeneic invariant natural killer T (iNKT) cell therapies (MiNK-215 and agenT-797).

Beyond the preview

Go deeper on AT313.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT313.

Explore the full profile